Skip to main content
. 2020 Dec 30;15(12):e0244183. doi: 10.1371/journal.pone.0244183

Fig 4.

Fig 4

A. Overall VA gains at Year 1 in patients who received prior ranibizumab treatment for <1 year. N, number of patients with evaluable baseline and 1-year data; VA, visual acuity. B. Overall VA letters lost at Year 1 in patients who received prior ranibizumab treatment for <1 year. *Includes patients with 0 letters loss. †At 1-year, vision was largely maintained in almost half (47.1%) of patients treated with ranibizumab for up to 1 year before entering LUMINOUS. N, number of patients with evaluable baseline and 1-year data; VA, visual acuity.